Document is current
Any future updates will be listed below
-
Authors
Friligkou, Eleni https://orcid.org/0009-0003-3682-0991
Koller, Dora https://orcid.org/0000-0002-0415-0466
Pathak, Gita A.
Miller, Edward J.
Lampert, Rachel
Stein, Murray B. https://orcid.org/0000-0001-9564-2871
Polimanti, Renato https://orcid.org/0000-0003-0745-6046
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32 MH014276, and K99 AG078503, RF1 MH132337, R33 DA047527)
- License Information
-
More Information
Article History
Received: 22 February 2024
Revised: 3 November 2024
Accepted: 7 November 2024
First Online: 18 November 2024
Competing interests
: RP reported receiving personal fees for editorial work on the journal Complex Psychiatry from Karger Publishers and a research grant from Alkermes outside the submitted work. MBS reported consulting for Acadia Pharmaceuticals Inc., Aptinyx Inc., ATAI Life Sciences, Biogen Inc., Bionomics, BigHealth, BioXcel Therapeutics Inc, Boehringer Ingelheim, Clexio Biosciences Ltd, Eisai Co Ltd, EmpowerPharm, Engrail Therapeutics, Janssen Pharmaceuticals, Jazz Pharmaceuticals, NeuroTrauma Sciences LLC, PureTech Health, Sage Therapeutics, Sumitomo Pharma Co Ltd, and Roche-Genentech; and receiving stock options from Oxeia Biopharmaceuticals Inc and EpiVario outside the submitted work; serving as editor in chief for Depression and Anxiety, deputy editor for Biological Psychiatry, and co-editor in chief for Psychiatry for UpToDate for compensation. RL reported receiving speaker honoraria, advisory board fees, and research funding from Medtronic; speaker honoraria and research funding from Abbott/St Jude; and research funding from Boston Scientific. EJM reported consulting for Eidos, Pfizer, Siemens, Alnylam, and Roivant and receiving research funding from Eidos, Pfizer, and Argospect. No other disclosures were reported.
